RUNX1 and acute myeloid leukemia: Being able to target the RUNX1/ETO fusion protein, which is a major driver in t(8;21)-dependent AML, has the potential to enable targeted therapy schemes with superior efficacy and lesser toxicities than conventional chemotherapy9.